Testing emactinib with chemo and immunotherapy before head and neck cancer surgery
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests whether combining the drug emactinib with chemotherapy and immunotherapy before surgery helps treat advanced head and neck cancer. It aims to shrink tumors and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced head and neck cancer (stage III or IVA) that can be operated on or may become operable.
- You are physically active and able to care for yourself (ECOG score 0-1).
- A blood test shows that more than 10% of your immune cells (CD8+ T cells) are a certain type that may respond to treatment.
- Your kidneys, liver, and blood cell counts are within a healthy range.
- You have not had prior treatment with immunotherapy or JAK inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of targeted immunotherapy and chemotherapy before surgery for people with advanced head and neck cancer (stage 3 or 4a). The goal is to see if this pre-treatment can shrink tumors and improve outcomes.
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Head and Neck Cancer Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.